What is a stock summary page? Click here for an overview.
Business Description
Beximco Pharmaceuticals Ltd
ISIN : US0885792061
Share Class Description:
FRA:R2WA: DRCompare
Compare
Traded in other countries / regions
BXPHARMA.BangladeshBXP.UKR2WA.Germany IPO Date
2007-08-03Description
Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.38 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | 0.67 | |||||
| Interest Coverage | 8.77 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.3 | |||||
| Beneish M-Score | -2.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.6 | |||||
| 3-Year EBITDA Growth Rate | 12.9 | |||||
| 3-Year EPS without NRI Growth Rate | 4.3 | |||||
| 3-Year FCF Growth Rate | 20.9 | |||||
| 3-Year Book Growth Rate | 9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 17.06 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 11.97 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.04 | |||||
| 9-Day RSI | 61.93 | |||||
| 14-Day RSI | 58.61 | |||||
| 3-1 Month Momentum % | 4.35 | |||||
| 6-1 Month Momentum % | 61.19 | |||||
| 12-1 Month Momentum % | -0.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.13 | |||||
| Quick Ratio | 0.83 | |||||
| Cash Ratio | 0.2 | |||||
| Days Inventory | 196.57 | |||||
| Days Sales Outstanding | 29.83 | |||||
| Days Payable | 50.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 6.78 | |||||
| Dividend Payout Ratio | 0.28 | |||||
| 3-Year Dividend Growth Rate | 36.9 | |||||
| Forward Dividend Yield % | 6.78 | |||||
| 5-Year Yield-on-Cost % | 26.53 | |||||
| Shareholder Yield % | 12.12 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 44.91 | |||||
| Operating Margin % | 19.64 | |||||
| Net Margin % | 13.71 | |||||
| FCF Margin % | 6.18 | |||||
| ROE % | 13.3 | |||||
| ROA % | 8.95 | |||||
| ROIC % | 10.99 | |||||
| 3-Year ROIIC % | 8.38 | |||||
| ROC (Joel Greenblatt) % | 16.72 | |||||
| ROCE % | 15.48 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 7.15 | |||||
| Forward PE Ratio | 3.37 | |||||
| PE Ratio without NRI | 7.15 | |||||
| Shiller PE Ratio | 10.35 | |||||
| Price-to-Owner-Earnings | 10.61 | |||||
| PEG Ratio | 0.44 | |||||
| PS Ratio | 0.98 | |||||
| PB Ratio | 0.92 | |||||
| Price-to-Tangible-Book | 1.1 | |||||
| Price-to-Free-Cash-Flow | 15.85 | |||||
| Price-to-Operating-Cash-Flow | 6.18 | |||||
| EV-to-EBIT | 6.14 | |||||
| EV-to-EBITDA | 6.14 | |||||
| EV-to-Forward-EBITDA | 6.77 | |||||
| EV-to-Revenue | 1.22 | |||||
| EV-to-Forward-Revenue | 1.69 | |||||
| EV-to-FCF | 18.58 | |||||
| Price-to-GF-Value | 0.52 | |||||
| Price-to-Projected-FCF | 0.62 | |||||
| Price-to-DCF (Earnings Based) | 0.17 | |||||
| Price-to-DCF (FCF Based) | 0.29 | |||||
| Price-to-Median-PS-Value | 0.52 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.89 | |||||
| Price-to-Graham-Number | 0.62 | |||||
| Earnings Yield (Greenblatt) % | 16.28 | |||||
| FCF Yield % | 5.81 | |||||
| Forward Rate of Return (Yacktman) % | 15.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beximco Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 366.299 | ||
| EPS (TTM) (€) | 0.112 | ||
| Beta | 0.56 | ||
| 3-Year Sharpe Ratio | -0.54 | ||
| 3-Year Sortino Ratio | -0.69 | ||
| Volatility % | 46.82 | ||
| 14-Day RSI | 58.61 | ||
| 14-Day ATR (€) | 0.014578 | ||
| 20-Day SMA (€) | 0.4349 | ||
| 12-1 Month Momentum % | -0.92 | ||
| 52-Week Range (€) | 0.236 - 0.492 | ||
| Shares Outstanding (Mil) | 446.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beximco Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Beximco Pharmaceuticals Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Beximco Pharmaceuticals Ltd Frequently Asked Questions
What is Beximco Pharmaceuticals Ltd(FRA:R2WA)'s stock price today?
The current price of FRA:R2WA is €0.46. The 52 week high of FRA:R2WA is €0.49 and 52 week low is €0.24.
When is next earnings date of Beximco Pharmaceuticals Ltd(FRA:R2WA)?
The next earnings date of Beximco Pharmaceuticals Ltd(FRA:R2WA) is 2025-04-30 Est..
Does Beximco Pharmaceuticals Ltd(FRA:R2WA) pay dividends? If so, how much?
The Dividend Yield %  of Beximco Pharmaceuticals Ltd(FRA:R2WA) is 6.78% (As of Today), Highest Dividend Payout Ratio of Beximco Pharmaceuticals Ltd(FRA:R2WA) was 0.34. The lowest was 0.09. And the median was 0.19. The  Forward Dividend Yield % of Beximco Pharmaceuticals Ltd(FRA:R2WA) is 6.78%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers